IP Library › Granted Patent US 12702669
Granted Patent B2
US 12702669 · App. 18/141,965 · Granted Aug 11, 2026

Compositions and methods for treating cancer

Inventor: Amyn Aziz Habib (Washington, DC)
Assignee: The United States Government as represented by the Department of Veterans Affairs
A61K31/517A61K31/454A61K31/573A61K38/1793A61K39/395A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12702669
App. No.
18/141,965
Granted
Aug 11, 2026
Kind
B2
Abstract

Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.

Claims (17)

1 . A method for treating lung cancer in a patient in need thereof, said method comprising administering to said patient an effective amount of afatinib and dexamethasone, wherein the lung cancer expresses EGFR wild type or an EGFR activating mutation.

2 . The method of claim 1 , wherein the lung cancer expresses EGFR having a T790M and/or a L858R mutation.

3 . The method of claim 1 , wherein the lung cancer is non-small cell lung cancer.

4 . The method of claim 2 , wherein the lung cancer expresses EGFR having a T790M mutation.

5 . The method of claim 2 , wherein the lung cancer expresses EGFR having a L858R mutation.

6 . The method of claim 2 , wherein the lung cancer expresses EGFR having a T790M and a L858R mutation.

7 . The method of claim 1 , wherein afatinib is administered concurrently with dexamethasone.

8 . The method of claim 1 , wherein the lung cancer expresses EGFR having an exon 19 deletion.

9 . The method of claim 1 , wherein afatinib and dexamethasone are present in a pharmaceutical composition.

10 . The method of claim 1 , wherein the patient is a human patient.

11 . A method for treating non-small cell lung cancer in a patient in need thereof, said method comprising concurrently administering to said patient an effective amount of afatinib and dexamethasone, wherein the non-small cell lung cancer expresses EGFR having a T790M and/or a L858R mutation.

12 . The method of claim 11 , wherein the lung cancer expresses EGFR having an exon 19 deletion.

13 . The method of claim 11 , wherein afatinib and dexamethasone are present in a pharmaceutical composition.

14 . The method of claim 11 , wherein the patient is a human patient.

15 . The method of claim 11 , wherein the lung cancer expresses EGFR having a T790M mutation.

16 . The method of claim 11 , wherein the lung cancer expresses EGFR having a L858R mutation.

17 . The method of claim 11 , wherein the lung cancer expresses EGFR having a T790M and a L858R mutation.